Ignota vacuums up Kronos Bio's drug programmes Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

#IgnotaLabs #KronosBio #acutemyeloidleukaemia #AML #ovariancancer #AI #SAFEPATHplatform #SAFEPATH #istisociclib #CDK9inhibitor #SYKinhibitors #entospletinib #lanraplenib #ConcentraBiosciences #iTeosTherapeutics #ElevationOncology #CARGOTherapeutics #TheseusPharma #JounceTherapeutics zurl.co/WkH2F